Literature DB >> 3176833

Effects of dopamine on the portal circulation after therapeutic hepatic artery ligation.

O Winsö1, B Biber, J Fornander, B Gustavsson, C Holm, J Häggendal, I Milsom.   

Abstract

The effects of exogenous dopamine (2, 4 and 6 micrograms.kg-1.min-1 i.v.) on the portal circulation were studied in six patients following therapeutic hepatic artery ligation. Portal blood flow (PBF) was measured by the continuous thermodilution technique. Portal venous pressure (PVP, n = 3) was monitored through the thermodilution catheter to allow derivation of preportal vascular resistance (PVR). Blood samples were taken through the portal venous catheter for measurement of dopamine. A significant increase in PBF and a decrease in PVR were observed during graded i.v. dopamine infusion. Thus, PBF was 961 +/- 119 ml.min-1 during control conditions and increased to 1446 +/- 221 ml.min-1 during the dopamine infusion at 6 micrograms.kg-1.min-1. No significant changes in mean arterial pressure or PVP were observed during dopamine administration. The pharmacokinetics of dopamine did not differ from that previously reported in patients with an intact arterial supply. In conclusion, our data indicate that exogenous dopamine consistently increases PBF by preportal vasodilation, also in patients with a surgically restricted hepatic arterial blood supply.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3176833     DOI: 10.1111/j.1399-6576.1988.tb02766.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  2 in total

1.  Impact of dopamine and endothelin-1 antagonism on portal venous blood flow during laparoscopic surgery.

Authors:  Z-G Kim; E Sanli; L Brinkmann; M Lorenz; C N Gutt
Journal:  Surg Endosc       Date:  2002-05-23       Impact factor: 4.584

2.  A population pharmacokinetic model of epidural lidocaine in geriatric patients: effects of low-dose dopamine.

Authors:  Andrea Kwa; Juraj Sprung; Michael Van Guilder; Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2008-06       Impact factor: 3.681

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.